公开(公告)号：US20120114637A1

公开(公告)日：2012-05-10

申请号：US13265530

申请日：2010-05-04

申请人： Thierry Nivaggioli ,  David A. Weber ,  Philippe JM Dor ,  Philip Reilly

发明人： Thierry Nivaggioli ,  David A. Weber ,  Philippe JM Dor ,  Philip Reilly

IPC分类号： A61K31/436 ,  A61K31/12 ,  A61K31/192 ,  A61K31/5377 ,  A61K31/409 ,  A61K31/58 ,  A61K31/4545 ,  A61K31/675 ,  A61P27/02 ,  A61K39/395 ,  A61K31/4745 ,  A61K31/404

CPC分类号： A61K31/573 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/436 ,  A61K31/506 ,  A61K31/519

摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.

摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是眼科制剂，其向受试者递送多种治疗剂，包括但不限于雷帕霉素（西罗莫司），其类似物（rapalog）或其他mTOR抑制剂）延长时间。 眼用制剂可以放置在受试者的水性介质中，包括但不限于眼内或眼周内给药或靠近受试者待治疗的疾病或病症的部位放置。 可以使用一种治疗剂来治疗或预防受试者中年龄相关性黄斑变性，黄斑水肿，糖尿病性视网膜病变，葡萄膜炎，干眼症或高渗透性疾病的方法。

公开(公告)号：US20120034279A1

公开(公告)日：2012-02-09

申请号：US13279179

申请日：2011-10-21

申请人： Eugene R. COOPER ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe JM Dor ,  Sreenivasu Mudumba

发明人： Eugene R. COOPER ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe JM Dor ,  Sreenivasu Mudumba

IPC分类号： A61K9/14 ,  A61P27/02 ,  A61K31/439

CPC分类号： A61K9/0048 ,  A61K9/0019 ,  A61K31/436

摘要： Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

摘要翻译： 通过将这些组织交叉施用治疗剂，可以有效地治疗与眼后段组织相关的疾病。 用于递送治疗剂使得它们穿过巩膜并到达这些组织的组合物，装置和方法包括在巩膜附近或在巩膜附近注射溶液或悬浮液，并植入包含与巩膜内或巩膜内的治疗剂的固体结构。 这些方法可用于施用雷帕霉素或相关化合物以治疗与年龄相关的黄斑变性相关的脉络膜新生血管形成。